NEW YORK – AnchorDx said Monday that it has entered into a long-term collaboration with DiaCarta aimed at product development and global commercialization in the cancer screening space.
Under the agreement, AnchorDx and DiaCarta will leverage proprietary technologies for DNA methylation and mutation detection that each company has developed.
Guangzhou, China-based AnchorDx's DNA methylation-based bladder cancer early detection test was granted a breakthrough device designation by the US Food and Drug Administration in July 2021. The firm is currently conducting a registrational and prospective clinical trial for the urine-based assay, dubbed UriFind, and Pleasanton, California-based DiaCarta will serve as one of the clinical testing laboratories.
"We are committed to bring the best cancer diagnostic products to global market. Toward that goal we are excited to work with the world-leading diagnostics company DiaCarta to commercialize our leading cancer screening products and codevelop future cancer screening tests," said AnchorDx Founder and CEO Jian-Bing Fan in a statement.
Financial terms of the agreement were not disclosed.